Skip to main content

Table 4 Quality of life, sleep quality, and physical activity. Baseline data and changes (%) in response to 12 months of treatment with melatonin or placebo. Median scores with 25–75 % interquartile range

From: The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial

 

Baseline

P-value

Changes after 12 months (%)

P-value*

Physical component score

 

0.69

 

0.16

 Placebo

54.9 (48.2;56.9)

 

1.80 (−3.79;7.11)

 

 Melatonin

54.7 (50.9;57.4)

 

−0.30 (−4.00;4.83)

 

Mental component score

 

0.12

 

0.94

 Placebo

56.6 (51.8;59.0)

 

−0.78 (−5.88;4.47)

 

 Melatonin

58.0 (55.6;59.5)

 

−0.34 (−6.13;4.12)

 

WHO-5 Well-being Index

 

0.63

 

0.27

 Placebo

80.0 (72.0;84.0)

 

0.00 (−9.52;5.00)

 

 Melatonin

80.0 (73.0;84.0)

 

0.00 (−5.00;5.56)

 

Pittsburgh Sleep Quality Index

 

0.36

 

0.31

 Placebo

5.0 (2.0;8.5)

 

0.00 (−32.14;38.33)

 

 Melatonin

4.5 (3.0;5.0)

 

0.00 (−41.11;28.79)

 

Pittsburgh Sleep Quality Index > 5

 

0.47

 

0.08

 Placebo, N = 20

8.5 (6.0;9.8)

 

−13.3 (−32.1;9.4)

 

 Meltonin, N = 9

8.0 (6.0;8.5)

 

−37.5 (−64.5;-15.5)

 

Physical activity scalea

 

0.17

 

0.43

 Placebo

43.8 (37.4;48.7)

 

−0.16 (−8.46;8.29)

 

 Melatonin

46.0 (40.9;51.3)

 

−2.27 (−13.84;10.07)

 
  1. *Percentage change between groups
  2. aMetabolic equivalent (MET) score for 24 hours